EZALLOR SPRINKLE
EZALLOR SPRINKLE- rosuvastatin calcium capsule
Sun Pharmaceutical Industries, Inc.
1 INDICATIONS AND USAGE
EZALLOR SPRINKLE is indicated:
- To reduce the risk of stroke, myocardial infarction, and arterial revascularization procedures in adults without established coronary heart disease who are at increased risk of cardiovascular (CV) disease based on age, hsCRP ≥2 mg/L, and at least one additional CV risk factor.
- As an adjunct to diet to:
- Reduce LDL-C in adults with primary hyperlipidemia.
- Reduce low-density lipoprotein cholesterol (LDL-C) and slow the progression of atherosclerosis in adults.
- Reduce LDL-C in adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH).
- As an adjunct to other LDL-C-lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 7 years and older with homozygous familial hypercholesterolemia (HoFH).
- As an adjunct to diet for the treatment of adults with:
- Primary dysbetalipoproteinemia.
- Hypertriglyceridemia.
2 DOSAGE AND ADMINISTRATION
2.1 General Dosage and Administration Information
- Administer EZALLOR SPRINKLE orally as a single dose at any time of day, with or without food. Swallow capsules whole. Do not crush or chew. Assess LDL-C when clinically appropriate, as early as 4 weeks after initiating EZALLOR SPRINKLE, and adjust the dosage if necessary.
- If a dose is missed, advise patients not take an extra dose. Resume treatment with the next dose.
2.2 Recommended Dosage in Adult Patients
- The dosage range for EZALLOR SPRINKLE is 5 mg to 40 mg orally once daily.
- The recommended dose of EZALLOR SPRINKLE depends on a patient’s indication for usage, LDL-C, and individual risk for cardiovascular events.
2.3 Recommended Dosage in Pediatric Patients
Dosage in Pediatric Patients 8 Years of Age and Older with HeFH
The recommended dosage range is 5 mg to 10 mg orally once daily in patients aged 8 years to less than 10 years and 5 mg to 20 mg orally once daily in patients aged 10 years and older.
Dosage in Pediatric Patients 7 Years of Age and Older with HoFH
The recommended dosage is 20 mg orally once daily.
2.4 Dosing in Asian Patients
Initiate EZALLOR SPRINKLE at 5 mg once daily due to increased rosuvastatin plasma concentrations. Consider the risks and benefits of EZALLOR SPRINKLE when treating Asian patients not adequately controlled at doses up to 20 mg once daily [see Warnings and Precautions (5.1), Use in Specific Populations (8.8), and Clinical Pharmacology (12.3)].
2.5 Recommended Dosage in Patients with Renal Impairment
In patients with severe renal impairment (CLcr less than 30 mL/min/1.73 m2) not on hemodialysis, the recommended starting dosage is 5 mg once daily and should not exceed 10 mg once daily [see Warnings and Precautions (5.1) and Use in Specific Populations (8.6)].
There are no dosage adjustment recommendations for patients with mild and moderate renal impairment.
2.6 Dosage and Administration Modifications Due to Drug Interactions
EZALLOR SPRINKLE Dosage Modifications Due to Drug Interactions
Table 1 displays dosage modifications for EZALLOR SPRINKLE due to drug interactions [see Warnings and Precautions (5.1) and Drug Interactions (7.1)].
Table 1: EZALLOR SPRINKLE Dosage Modifications Due to Drug Interactions
Concomitantly Used Drug | EZALLOR SPRINKLE Dosage Modifications |
Cyclosporine | Do not exceed 5 mg once daily. |
Teriflunomide | Do not exceed 10 mg once daily. |
Enasidenib | Do not exceed 10 mg once daily. |
Capmatinib | Do not exceed 10 mg once daily. |
Fostamatinib | Do not exceed 20 mg once daily. |
Febuxostat | Do not exceed 20 mg once daily. |
Gemfibrozil | Avoid concomitant use. If used concomitantly, initiate at 5 mg once daily and do not exceed 10 mg once daily. |
Tafamidis | Avoid concomitant use. If used concomitantly, initiate at 5 mg once daily and do not exceed 20 mg once daily. |
Antiviral Medications | |
| Concomitant use not recommended. |
| Initiate at 5 mg once daily. Do not exceed 10 mg once daily. |
Darolutamide | Do not exceed 5 mg once daily. |
Regorafenib | Do not exceed 10 mg once daily. |
EZALLOR SPRINKLE Administration Modifications Due to Drug Interactions
When taking EZALLOR SPRINKLE with an aluminum and magnesium hydroxide combination antacid, administer EZALLOR SPRINKLE at least 2 hours before the antacid [see Drug Interactions (7.2)].
2.7 Preparation and Administration Instructions
EZALLOR SPRINKLE capsule should be swallowed whole. For patients unable to swallow an intact capsule, consider the following instructions based on the route of administration and refer to the accompanying Instructions for Use for complete administration instructions:
Oral Administration
- Carefully open the capsule and sprinkle the entire contents of the capsule onto at least one teaspoonful (5 mL) of room temperature applesauce or chocolate/vanilla flavored pudding.
- Stir the mixture for 10 to 15 seconds.
- Swallow the entire mixture within 60 minutes of mixing. Do not chew the mixture.
- Do not save the mixture for later use.
- Discard the unused portion immediately.
Nasogastric Tube (≥16 French) Administration
- Carefully open the capsule and empty the intact granules emptied into a 60 mL catheter tipped syringe barrel and add 40 mL of water. Do not use with liquids other than water.
- Replace the plunger and shake the syringe vigorously for 15 seconds. The granules in EZALLOR SPRINKLE capsule may start dissolving which is acceptable.
- Attach the syringe to a nasogastric tube (≥16-French) and deliver the contents of the syringe through the nasogastric tube into the stomach.
- Flush the nasogastric tube should with 20 mL of additional water after administering the mixture.
- Do not save the mixture for later use.
- Discard the unused portion immediately.
3 DOSAGE FORMS AND STRENGTHS
5 mg: Hard gelatin capsule, Size “3” pink cap/off white body, imprinted axially with “984” on cap and body in black ink filled with yellow colored granules.
10 mg: Hard gelatin capsule, Size “3” purple cap/off white body, imprinted axially with “985” on cap and body in black ink filled with yellow colored granules.
20 mg: Hard gelatin capsule, Size “1” blue cap/off white body, imprinted axially with “986” on cap and body in black ink filled with yellow colored granules.
40 mg: Hard gelatin capsule, Size “0el” green cap/white body, imprinted axially with “987” on cap and body in black ink filled with yellow colored granules.
4 CONTRAINDICATIONS
EZALLOR SPRINKLE is contraindicated in the following conditions:
- Acute liver failure or decompensated cirrhosis [see Warnings and Precautions (5.3)].
- Hypersensitivity to rosuvastatin or any excipients in EZALLOR SPRINKLE. Hypersensitivity reactions including rash, pruritus, urticaria, and angioedema have been reported with EZALLOR SPRINKLE [see Adverse Reactions (6.1)].
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.